Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of the "Prefilled Syringes in 2017 & Beyond" report to their offering.
The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. Population demographics and efforts by managed care providers to control healthcare costs are driving the growth in drug self-administration, particularly for chronic conditions, introducing a new class of naïve users to parenteral drug delivery.
For Fill-and-Finish contractors, market proximity is an important competitive factor. As the use of prefilled syringes continues to grow, the issue of prefilled syringe safety has received increased attention, with both integrated prefillable safety syringes and safety solutions designed to accommodate existing prefillable syringes advancing commercially. This report analyzes eleven important prefilled syringe therapeutic segments and examines key regulatory, economic and competitive factors that represent potential barriers to commercial success.
What You Will Learn
- What drugs are supplied in prefilled syringes, what are the drug + device specifics, and who markets them?
- Who are the branded prefilled syringe suppliers, their manufacturing infrastructure and locations, their capabilities?
- What are the major factors driving prefilled syringe demand?
- What is the importance of industry collaborations on commercial success and what are the specifics of these partnerships and alliances
- What are the essential design factors, material selection issues, technologies and market development issues for prefilled injectable drug products?
- What are prefilled device categories that compete with prefilled syringes and what is their market share?
- What are the significant economic, technology, and regulatory factors affecting the market for prefilled syringes?
Key Topics Covered:
1. Executive Summary
2. Prefilled Syringes in 2017 and Beyond
- The Prefilled Device Landscape
- Prefilled Syringe Market Drivers
- Innovation in Prefillable Device Designs
- Evolution of the Fill/Finish Ecosystem
- Incidence of Chronic Conditions
- NMEs and the Treatment of Refractory Diseases
- Therapeutic Demand Drivers for PFS
- Commercial Landscape - Competition & Collaboration
3. Prefilled Syringes - Design Factors
- Drug Stability and Shelf Life
- Material Selection Issues
- Point-of-Use Reconstitution
- Caregiver Safety
- Human Engineering/Ergonomics
4. Prefilled Syringes - Commercial Devices
- Prefillable Therapeutic Injectables
- Glass Prefillable Syringes
- Plastic Prefillable Syringes
- Ready-to-Fill Safety Syringes
- Specialty Prefillable Syringes
- Flush Syringes
- Diluent Syringes
- Imaging Agent Syringes
5. Prefilled Syringe Market Segments - Market Data & Forecasts
- Anaphylaxis
- Anticoagulants
- Autoimmune Diseases
- Emergency Medicine
- Hepatitis
- Hematopoietics and Related ESPs
- Metabolic Diseases
- Neurology
- Reproductive Health
- Vaccines
6. Market Factors
- Regulatory Issues
- Device Branding
- Patient Compliance and Ease of Use
- Healthcare Economics
- PFS Sector Partnerships and Alliances
7. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/xp66dx/prefilled
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables , Needles and Syringes


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anta Sports Expands Global Footprint With Strategic Puma Stake
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



